Enter search term

News

ZEUS dIFine™ ANA Hep-2 IFA Submitted to FDA

Aug 14, 2020

The best slides deserve the best in class automation.  We have completed the next step by submitting the ZEUS dIFine™ to the FDA last month.  We are taking your ANA IFA testing to the next level by pairing our IFA ANA Hep-2 with our dIFine™ system.

Read More

Integrate COVID-19 Antibody Testing Simply & Effectively

Jul 31, 2020

While the world continues to deal with the COVID-19 pandemic, ZEUS recognizes the challenges facing resource strained labs as pre-pandemic test volumes rebound while absorbing the additional COVID-19 testing demands.  ZEUS offers two SARS-CoV-2 antibody test systems which seamlessly integrates with our broad range of ELISA assays, spanning across autoimmune and infectious disease testing.

Read More

ZEUS Scientific: American Expertise in Every American-Made Test

Jul 1, 2020

ZEUS Scientific Is a Proud American CompanyDoing our Part in the Fight Against COVID-19

 We have a long history of developing, manufacturing and delivering IVD kits for infectious and autoimmune disease testing.  With over 125 FDA cleared assays in our menu, we continue to apply our expertise of developing tests to detect human antibodies to a number of different viruses including SARS-CoV-2.  For decades, laboratories have trusted ZEUS and now is the time to maintain confidence in ZEUS as we all continue the battle against the COVID-19 pandemic and SARS-CoV-2 virus.

 

Read More

NEW! ZEUS ELISA SARS-CoV-2 Total Antibody Test System EUA Submitted, Validated, and Ready for distribution

Jun 15, 2020

ZEUS Scientific announced today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of Total (IgG, IgM, IgA)  antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now. 

Read More

ZEUS Rapid SARS-CoV-2 IgM/IgG Antibody Test System: Delivering confidence in results

Jun 11, 2020

ZEUS Rapid SARS-CoV-2 IgM/IgG has been validated according to FDA guidelines established for serological assays, meeting the criteria to be distributed to where it is needed most. In response to the many inferior SARS-CoV-2 antibody tests flooding the market, the U.S FDA strengthened their data requirements to obtain an Emergency Use Authorization (EUA) for a COVID-19 antibody test.  ZEUS immediately reacted by conducting a USA study of clinically characterized specimens that confirms the superior performance of our Rapid SARS-CoV-2 IgM/IgG Test System.  ZEUS Scientific has heard your requests for help and is committed to providing quality easy-to-use solutions that will help address the public health threat posed by COVID-19.

Read More

ZEUS Scientific Announces NEW ZEUS ELISA SARS-CoV-2 IgG Test System

Jun 5, 2020

ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of IgG antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS has notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now.

Read More

Let us put 40+ years of diagnostic experience to fight COVID-19 with you

May 27, 2020

In this time of crisis, we are here to help. For over 40 years ZEUS Scientific has developed, manufactured and sold in vitro diagnostic test kits for infectious and autoimmune disease testing. We have allocated the majority of our resources to produce serological antibody tests to combat the SARS-CoV-2 virus.  For decades, many of our products were built to detect human antibodies to a number of different viruses and we have now applied that knowledge to help in the fight with the COVID-19 pandemic.

Read More

Automated SARS-CoV-2 Antibody Tests

May 14, 2020

COMING SOON: ZEUS ELISA SARS CoV-2 Test System!

  • Do you have serological samples from confirmed PCR-positive COVID-19 patients?
  • Can we collaborate to validate assay performance for SARS-CoV-2 antibody testing?
Read More

FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses

Jul 30, 2019

Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test. 

Read More

ZEUS Scientific to offer its ZEUS IFA™ product line directly to customers in the United States

Dec 10, 2018

ZEUS Scientific has announced that as of January 1st, 2019, ZEUS will assume all sales, marketing and support functions for all ZEUS IFA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.

Read More

Dynex® Technologies announces global partnership with ZEUS Scientific

Jul 27, 2018

Dynex Technologies has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ) enabling ZEUS to sell Dynex instruments to the global clinical market. This new direct partnership builds on the long standing relationship between both companies with Dynex Technologies’ industry proven DS2®, DSX® and Agility® automated ELISA instrumentation and ZEUS Scientific’s broad range of ZEUS ELISA™ Test Systems which use common reagents and universal protocols across a diverse autoimmune and infectious disease menu.

Read More

ZEUS Scientific to offer its ZEUS ELISA™ product lines directly to customers in the United States

Dec 20, 2017

ZEUS Scientific has announced that as of February 1st, 2018, ZEUS will assume all sales, marketing and support functions for all ZEUS ELISA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.

Read More

ZEUS Scientific announces U.S. FDA Premarket Approvals (PMA) and launch of its ZEUS ELISA™ Parvovirus B19 Test Systems

Sep 21, 2017

ZEUS Scientific announces the launch of ZEUS ELISA Parvovirus B19 IgG and IgM Test Systems, following receipt of Premarket Approvals (PMA) from the U.S. Food and Drug Administration (USFDA). ZEUS ELISA Parvovirus B19 Test Systems are the latest addition to the company’s market leading range of infectious disease diagnostic solutions with seamless integration into the ZEUS ELISA menu of Test Systems. These test systems feature universal reagents and protocol, assay protocol with more flexible incubation times than any other currently available ELISA method, and quick adoption into the lab due to minimal training, enabling in-house testing.

Read More

ZEUS Scientific Assumes All Support Functions for AtheNA Multi-Lyte Test Systems

Jul 19, 2016

As of June 14th, 2016, ZEUS Scientific has assumed all the sales, marketing and support functions for all of the AtheNA Multi-Lyte test systems, instruments and consumables for our customers based in the United States. Contact ZEUS directly to find out more about how these multiplex, fluorescent, bead-based assays offer a simple and efficient testing alternative. Be sure that no well is missed with SAVe Diluent(TM), and discover how our proprietary Intra-Well Calibration Technology(R) reduces the number of non-reportable wells in every run to maximize your value in choosing this unique platform!

Read More

AMA Adds New CPT Code for SPLA2-IIA Measurement for Cardiovascular Risk Assessment

Jul 23, 2015

ZEUS Scientific has been notified by the American Medical Association (AMA) that the Current Procedural Terminology (CPT) Editorial Panel has accepted its request to add code 0423T to report a test for measurement of secretory type II phospholipase A2 (sPLA2-IIA) protein for assessment of level of risk for cardiovascular event. The code has been posted to the AMA CPT website with an effective implementation date of January 1, 2016.

Read More